LONDON, United Kingdom — (BUSINESS WIRE)– It has been a decade since I saw a man with cancer.
And I never expected to be a patient of the London-based, British-based company, Novartis, that invented a drug that I believe will change the way the world treats and treats patients with rare and life-threatening cancers.
The company is based in the UK, and NovartIS is based here in London, where I have been working on my PhD research.
But the world has changed in the past decade.
Our lives are increasingly connected, our digital devices are constantly changing and new types of cancers are being diagnosed more frequently.
I’m no longer able to go to the hospital for routine treatments for my cancer, or get the chemotherapy that is being prescribed to me.
And my colleagues and I have to wait for days or weeks for a new test, a new dose of radiation or a new treatment.
We live in a world where a single cancer diagnosis can take up to a year to find and then there are treatments for other types of cancer that have been around for decades.
I know I will never be cured, but I do believe that if we can develop a drug, a treatment that can quickly be delivered and quickly be taken on, it will be worth waiting.
NovartIS has developed an experimental drug that uses a new protein to deliver the same cancer-killing action to cancer cells.
This new drug, called Kymo, is the first drug approved by the European Medicines Agency to treat a cancerous cell line known as G6PDC (granuloma multiforme), which is a type of breast cancer.
G6 PDC is a very aggressive, very dangerous form of cancer.
It has become a significant public health concern, with an estimated 500,000 new cases every year.
G6 PDCs have become a global threat, with the highest incidence rates in China, India and the United States.
These cancers are most often caused by mutations in a gene called CD28, which is present in about 50 percent of the human genome.
These mutations, called mutations in the G6P gene, are the genetic cause of breast cancers, but they can also cause tumors in other organs, including the liver and lungs.
The Kymosin gene, also known as CD28-G6PD, encodes a protein that delivers a protein called a Kymin to tumors, which are made up of a protein-protein interaction domain and a glycoprotein that binds to the cancerous cells.
The Kymins also have a protective effect, protecting cells from damaging and attacking the tumor.
This is because the Kyminos are proteins that are normally produced by normal cells, which in this case are G6 cells.
When the Kyns are removed from tumors, the Kys are removed, and the normal cells are no longer required to produce the Kyds.
That means there is a massive increase in the number of cancerous G6 tumors, and those that are resistant to the Kypins can become cancerous and kill the patient.
The drug KymoSin has a much shorter half-life compared to other drugs that target the same receptor in cancer cells, and is able to deliver a higher dose to tumors in a matter of hours, rather than days or even weeks.
The new drug will also be delivered by nanoparticles that are embedded in the cell, so they don’t need to be injected into a tumor and there is no need to use a chemotherapy.
It will also have less side effects, and patients can get the drug without having to go in for chemo.
The drug will be able to be delivered in a few hours, and it can be taken within days.
Novartsis has also developed a new technique to deliver drugs to tumors from within the body.
The nanoparticles are injected into the bloodstream, where they are then removed and the drugs are delivered.
Patients will receive the drugs within a few days.
There is also a new approach to delivery.
The drugs are injected directly into the tumor, which then is removed and then the drug is injected into other parts of the body, including into the brain.
Novartins scientists are now working to improve the nanoparticle delivery to reduce side effects.
The company believes that its drug is the “most exciting development in years of research in the development of nanoparticles for cancer treatment” and that it will eventually be available in the U.S. as well as other countries around the world.
It also announced that it has received an investment from a new angel investor, which will enable it to raise additional funding for further development of its drug.
NovARTIS is currently developing its drug in two phases: Phase 1 of the trial will include testing the drug on human tumors, followed by Phase 2 which will evaluate whether the drug has an effect on other cancers.
Both trials will begin in 2019.
NovARTIS believes that Phase